DNA-methylation dynamics across short-term, exposure-containing CBT in patients with panic disorder

Sylvain Moser1,2, Jade Martins3, Darina Czamara3

  • 1Department of Translational Research in Psychiatry, Max Planck Institute of Psychiatry, Munich, Germany. sylvain_moser@psych.mpg.de.

Translational Psychiatry
|February 2, 2022
PubMed

Insights

This study reveals epigenetic changes in panic disorder (PD) patients undergoing cognitive behavioral therapy (CBT). DNA methylation of the serotonin receptor 3A (HTR3A) and immune cell shifts are linked to therapy outcomes, offering potential biomarkers for treatment success.

Area of Science:

  • Neuroscience
  • Psychiatry
  • Immunology

Background:

  • Panic Disorder (PD) etiology is linked to genetic and environmental factors interacting via epigenetic mechanisms.
  • Cognitive Behavioral Therapy (CBT) is effective for PD, but its biological underpinnings are unclear.
  • Understanding epigenetic and immune correlates of CBT is crucial for identifying therapy biomarkers.

Purpose of the Study:

  • To investigate DNA methylation and immune cell composition changes during CBT and exposure therapy in PD patients.
  • To identify potential epigenetic and immune biomarkers associated with CBT treatment success.
  • To elucidate the biological mechanisms of action for CBT in Panic Disorder.

Main Methods:

  • Epigenome-wide association study (EWAS) analyzing DNA methylation.
  • Flow cytometry to assess immune cell-type composition.
  • Longitudinal study design tracking changes during CBT and exposure interventions.

Main Results:

  • Transient regulation of CD4+ T-Cells, Natural Killer cells, and Granulocytes during exposure.
  • Significant shifts in CD4+ T cells, CD8+ T cells, B-Cells, and Granulocytes proportions during therapy.
  • Differential methylation of HTR3A (cg01586609) during fear exposure, linked to treatment outcomes.
  • Long-lasting methylation changes in ARG1 (cg01699630) during therapy.

Conclusions:

  • First data-driven biological candidates for epigenetically mediated effects of fear exposure and CBT in PD.
  • HTR3A methylation and expression changes during fear exposure are associated with CBT trajectories and outcomes.
  • Findings suggest HTR3A as a potential biomarker for therapy success in PD.
  • Results support the role of immune system alterations in PD and response to treatment.

Related Concept Videos

Panic Disorder01:27

Panic Disorder

Panic disorder is an anxiety disorder characterized by recurrent and sudden minutes-long episodes of intense fear, known as panic attacks. These attacks may feel like heart attacks and often happen without warning or a specific cause. They can include symptoms such as rapid heart rate, shortness of breath, chest pain, trembling, sweating, dizziness, and a sense of helplessness. During a panic attack, individuals may feel as though they are experiencing a heart attack or are in a...
194
Behavior Therapy01:22

Behavior Therapy

Behavior therapy incorporates diverse techniques rooted in classical conditioning principles to address maladaptive behaviors and anxiety disorders. These methods aim to reduce avoidance behaviors, foster adaptive coping mechanisms, and alter associations between stimuli and responses, making them effective in a wide range of therapeutic contexts.
Exposure therapy is a cornerstone of behavioral treatment for anxiety disorders. It involves systematic exposure to feared stimuli, either in real...
162
Cognitive Therapy01:25

Cognitive Therapy

Cognitive therapy, pioneered by Aaron T. Beck in the 1960s, is a structured approach to addressing psychological distress by focusing on the influence of thoughts on emotions and behaviors. All cognitive therapies involve the basic assumption that human beings have control over their feelings, and that how individuals feel about something depends on how they think about it. Unlike psychoanalytic methods that delve into unconscious processes or humanistic approaches emphasizing...
497